Recent clinical study for Belight3 shows decrease in hyperpigmentation for all skin types

Image | adobe.stock/Angelina

A recent clinical study delved into using the branded ingredient, Belight³, for the purpose of decreasing hyperpigmentation, as well as encouraging even-toned skin. Belight³ is a nutritional supplement containing a patented blend of licorice extract, coated vitamin C, grape seed extract, and grape pomace extract. The press release mentioned that this blend works to restrain tyrosinase activity by 85%. Around the world, more than 50% of the population suffer from a variety of health concerns such as, post-inflammatory hyperpigmentation (PIH), melasma, and solar lentigo.¹

The study utilized participants with Caucasian skin (phototypes 1-3) which showed an increase of lightening regarding dark spots and skin complexion by +22%. Participants consisted of 66 women and men between the ages of 28 to 52 years old who were assigned to take either the placebo or Belight³. These findings were looked over by a dermatologist. Participants took one capsule of the placebo or Belight³ per day in the morning as they had breakfast with a glass of water and this took place every day over 12 weeks.² Researching staff ensured compliance of treatment by “counting the numbers of remaining capsules in the bottles at each visit.”² Additionally, the study took place during the winter months and “focused on participants with naturally lighter skin tones, younger age, and lower sun exposure, reinforcing the solution's effectiveness in various environmental conditions.”

After 11 days during the study, researchers saw visible improvements. There was a consumer satisfaction rate of 82% and potential benefits seen across a variety of skin tones.

Previous research was conducted on Asian skin (phototypes 3-4), as mentioned in the press release. Researchers found that Belight³ when compared to the placebo, reduced dark spots. According to the press release, Asian skin may be more susceptible to hyperpigmentation. This may be caused from increased sun exposure, genetic predisposition, and aging.

Activ’Inside will be hosting two webinars detailing Belight³ and its possible benefits by offering attendees viewing options in both Europe and the Americas.

Details for the webinar titled, “Targeting Hyperpigmentation: The Nutraceutical Solution for Even Skin” are below:

Market: EUROPE

Date: 27 FEB 2025

Time: 10:30 - 11:30 (UTC+01:00)

To Sign Up: https://events.teams.microsoft.com/event/c88cff53-4a7b-42c7-8433-1cccd9c16c50@88fb648b-2f72-40b1-9345-728aff508393

Market: The Americas

Date: 27 FEB 2025

Time : 12:00 - 13:00 (UTC-05:00)

To Sign Up: https://events.teams.microsoft.com/event/2382b67d-4885-4d0d-a6b4-b82392817105@88fb648b-2f72-40b1-9345-728aff508393

References

1. IMCAS 2024 pigmentary disorders prevalence impact on quality of life social stigmatization https://www.lorealdermatologicalbeauty.com/brazil/la-roche-posay/posters/imcas-posters/imcas-2024-pigmentary-disorders-prevalence-impact-on-quality-of-life-social-stigmatization (accessed Feb 11, 2025).
2. Tursi, F.; Pourtau, L.; Roveda, G.; De Ponti, I.; Gaudout, D.; Moras, B.; Pouchieu, C.; Nobile, V. Clinical Efficacy of Belight^3TM on Dark Spot Pigmentation in Caucasian Subjects. Cosmetics 2025, 12, 27. https://doi.org/10.3390/cosmetics12010027